Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 50: 2236-2237, 2004; 10.1373/clinchem.2004.042978
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khalil, O. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khalil, O. S.
Related Collections
Right arrow Point-of-Care Testing
Right arrow Endocrinology and Metabolism
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2004;50:2236-2237.)
© 2004 American Association for Clinical Chemistry, Inc.


Editorials

Noninvasive Photonic-Crystal Material for Sensing Glucose in Tears

Omar S. Khalil

1 Abbott Laboratories, Diagnostics Division, 100 Abbott Park Rd., Abbott Park, IL 60064, E-mail Omar.khalil{at}abbott.com

Most noninvasive (NI) methods for the determination of glucose either detect a small specific glucose signal or measure the effect of glucose on a tissue optical property (1)(2). A recent review identified the three main issues in NI glucose measurements as specificity, compartmentalization of glucose values, and calibration (1). This editorial discusses a photonic crystal method (3), with respect to these issues.

Asher’s group have developed a novel photonic sensing material that responds to glucose concentrations via diffraction of visible light. Polymerized crystalline colloidal arrays (PCCAs) are periodic crystalline lattices of polystyrene microspheres polymerized within thin hydrogel films (3)(4)(5)(6)(7). The arrays are brightly colored and act as diffraction gratings for white light according to the Bragg diffraction equation (4)(5):

(1)
In Eq. 1Up , n is the refractive index of the system (medium, hydrogel, and colloids), d is the spacing between the diffracting planes, {lambda} is the diffracted wavelength, and {Theta} is the glancing angle between the incident light and the diffracting planes. A change in electric charge in the PCCAs resulting from binding of molecular or ionic species causes changes the spacing, d, and there is a subsequent wavelength shift, {Delta}{lambda}, of the light reflected off the array.

Asher’s group have constructed a photonic glucose sensor in the form of thin acrylamide PCCA hydrogel films that contain glucose molecular recognition elements (3)(6)(7). Phenylboronic acid derivatives in the lattice bind glucose, causing a change in charge distribution and a blue shift, –{Delta}{lambda}, in the diffracted light (3). In vitro experiments showed that {Delta}{lambda} responded to changes in glucose concentration with highest sensitivity at glucose concentrations <10 mmol/L (3)(6)(7). The magnitude of the blue shift decreased as a function of glucose concentration when glucose approached 20 mmol/L (3). This made the PCCAs suitable only for detection of the tear-glucose concentration, which is considerably lower than that of blood. The PCCA lattice shrinks as the glucose concentration increases (3) and possibly reaches a lower limit where minimal {Delta}{lambda} is observed. The authors conceive using the polymer film sensor as a contact lens that changes color according to the glucose concentration in tears.

Boronic acid fluorophores embedded in a commercial contact lens and immersed in glucose solutions undergo changes in fluorescence intensity and wavelength on binding to glucose (8). The fluorescent contact lens film has the highest sensitivity at low glucose concentrations, which correspond to those in tear fluid.

The novelty and the sensitivity of PCCAs at low glucose concentrations are the impetus for this editorial, in which I examine the contact lens construct as a NI glucose testing modality.

The detection method depends on interaction between glucose and a specific binding molecule. It will have a specificity advantage over near-infrared absorption and scattering methods, but successful application in vivo is awaited. The dynamic range is limited to the glucose concentration in tears (3). The reversibility of the {Delta}{lambda} change on a reverse in the change in glucose concentration must be demonstrated in animal models and in human volunteers.

Current patient care is based on measurement of glucose in venous blood or arterialized venous blood. NI methods attempt to determine glucose in other body fluids, such as in tissue interstitial fluid, eye vitreous fluid, or tears, as substitutes for venous or capillary blood glucose. NI-determined glucose values in any body compartment must track changes in blood glucose without a lag time (9). This may not be the case when changes in blood glucose concentrations are sudden and are of too large a magnitude to allow for equilibration between the vascular compartment and other body compartments (1)(9)(10). Even for blood glucose measurements, there are site-specific rates of increase and decrease in blood glucose values (10). Equilibration between glucose in the blood and in other body fluids is a controversial issue with widely different reported lag times (1). Alexeev et al. (3) propose using photonic contact lens sensors with tears as the body fluid. The relative concentrations and lag times between glucose concentrations in tears and in the vascular system will require detailed studies.

Tears are generated in the lachrymal glands, and external stimuli affect the rate of tear generation. There are limited reports on the relationship between tear and blood glucose concentrations. The relationship seems to depend on the sampling method for tears and the extent of eye irritation during sampling (11). Earlier tear-glucose studies were semiquantitative because the investigators used color strips, and they did not include glucose surge experiments.

Gassett et al. (12) showed that in an oral glucose tolerance test (OGTT), tear-glucose concentrations tracked blood glucose with a time lag (from graph) of ~20 min. The mean (SD) tear glucose value for 30 nondiabetic individuals was 0.24 (0.17) mmol/L, and that of blood was 4.4 (1.7) mmol/L (12).

Citing earlier studies, Van Haeringen (11) concluded that there was no significant increase in tear-glucose concentrations when blood glucose concentrations were >20 mmol/L, which he considered to indicate that the corneal and conjunctival epithelium acted as a barrier against glucose transfer from tissues into the tear fluid. Tissue fluid, and not the lachrymal gland fluid, contributed to the "tear glucose" after mechanically stimulated methods of collection, making the relationship between tear glucose and blood glucose concentrations similar to that between blood glucose and tissue fluid (11).

Daum and Hill (13) reported a mean tear-glucose concentration of 0.42 (0.36) mmol/L for 12 nondiabetic individuals. The tear-glucose concentration generally tracked blood glucose during the day. Tear-glucose concentrations can be increased by mild abrasion of the conjunctival epithelium and exposure to hypotonic solutions. Nonmechanical stimuli that cause reflux tears, such as light flashes and noxious vapors, decrease tear-glucose concentrations (13). The authors of a recent study reported the result of an OGTT, without showing correlation data, as "the tear glucose levels maintained a more or less steady relationship with blood glucose level" (14).

With these limited reports on the relationship between tear and blood glucose, the critical test is measurement of {Delta}{lambda} for a PCCA as a function of blood glucose concentration in an animal model and/or human volunteers.

The presented PCCA data suggest a simple in vitro calibration of {Delta}{lambda} vs tear-glucose concentration in artificial tear fluid (3), but in vivo calibration must correlate {Delta}{lambda} with the blood glucose concentration. If lag times or other confounding factors are found, algorithms that account for these factors will be needed. The effects of eye irritation, lachrymating agents, and environment must be studied. It is important to decide whether the readout will be visual and semiquantitative, using color charts, or quantitative, using a spectrometric device. Although the simplicity of the calibration is quite encouraging, in vivo animal and human experiments are needed to address calibration issues, some of which are: How is the contact lens testing device to be calibrated? Is it a single-person calibration or multiple-person calibration? Will the readout device be calibrated by the manufacturer, or can the user calibrate it? What other inputs are required for the calibration?

The simplicity and novelty of this method are quite striking. In vivo animal and human experiments are needed to delineate the potential and the limitations of this interesting technology.


References

  1. Khalil OS. Non-invasive glucose measurement technologies: an update from 1999 to the dawn of the new millennium. Diabetes Technol Ther 2004;6:660-697.
  2. Khalil OS. Spectroscopic and clinical aspects of noninvasive glucose measurements. Clin Chem 1999;45:165-177.[Abstract/Free Full Text]
  3. Alexeev VL, Das S, Finegold DN, Asher SA. Photonic crystal glucose-sensing material for noninvasive monitoring of glucose in tear fluid. Clin Chem 2004;50:2362-2369.
  4. Holtz JH, Asher SA. Polymerized colloidal crystal hydrogel films as intelligent chemical sensing materials. Nature 1997;389:829-832.[CrossRef][Medline] [Order article via Infotrieve]
  5. Reese E, Baltusavich ME, Keim JP, Asher SA. Development of an intelligent polymerized crystalline colloidal array colorimetric reagent. Anal Chem 2001;73:5038-5042.[Medline] [Order article via Infotrieve]
  6. Alexeev VL, Sharma AC, Goponenko AV, Das S, Lednev IK, Wilcox CS, et al. High ionic strength glucose-sensing photonic crystal. Anal Chem 2003;75:2316-2323.[Medline] [Order article via Infotrieve]
  7. Asher SA, Alexeev VL, Goponenko AV, Sharma AC, Lednev IK, Wilcox CS, et al. Photonic crystal carbohydrate sensors: low ionic strength sugar sensing. J Am Chem Soc 2003;125:3322-3329.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  8. Badugu R, Lakowicz JR, Geddes CD. Noninvasive continuous monitoring of physiological glucose using a monosaccharide-sensing contact lens. Anal Chem 2004;76:610-618.[Medline] [Order article via Infotrieve]
  9. Heinemann L, Koschinsky T. Continuous glucose monitoring: an overview of today’s technologies and their clinical applications [Review]. Int J Clin Pract Suppl 2002;129:75-79.
  10. Koschinsky T, Jungheim K, Heinemann L. Glucose sensors and alternate site testing-like phenomenon: relationship between rapid blood glucose changes and glucose sensor signals. Diabetes Technol Ther 2003;5:829-842.[CrossRef][Medline] [Order article via Infotrieve]
  11. Van Haeringen NJ. Clinical biochemistry of tears. Surv Ophthalmol 1981;26:84-96.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  12. Gasset AR, Braverman LE, Fleming MC, Arky RA, Alter BR. Tear glucose detection in hyperglycemia. Am Opthalmol J 1968;65:414-420.
  13. Daum KM, Hill RM. Human tear glucose. Invest Ophthalmol Vis Sci 1982;22:509-514.[Abstract/Free Full Text]
  14. Chatterjee PR, De S, Datta H, Chatterjee S, Biswas MC, Sarkar K, et al. Estimation of tear glucose level and its role as a prompt indicator of blood sugar level. J Indian Med Assoc 2003;101:481-483.[Medline] [Order article via Infotrieve]



eLetters:

Read all eLetters

Response to your editorial on PCCA glucose sensors
Anjal C Sharma
Clinical Chemistry Online, 28 Jan 2005 [Full text]
Response to comments on the Photonic Crystal Glucose-sensor Editorial
Omar S Khalil
Clinical Chemistry Online, 2 Feb 2005 [Full text]
Re: Response to your editorial on PCCA glucose sensors
sanford a. asher
Clinical Chemistry Online, 28 Mar 2005 [Full text]
Re: Re: Response to your editorial on PCCA glucose sensors
Anjal C. Sharma
Clinical Chemistry Online, 19 May 2005 [Full text]

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khalil, O. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khalil, O. S.
Related Collections
Right arrow Point-of-Care Testing
Right arrow Endocrinology and Metabolism
Right arrow Automation and Analytical Techniques


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS